Last updated on April 2019

Evaluation of EYS606 in Patients With Non-infectious Posterior Intermediate or Panuveitis

Brief description of study

Primary objective: safety and tolerability

Secondary objectives: additional indicators of long term safety and indicators of clinical activity

Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and biomarkers

Detailed Study Description

The maximum study duration per patient is 27 Weeks (including an up to 3 week screening period + 24 weeks follow-up after treatment).

The study is conducted in 2 parts. Part 1 is a dose escalation phase which will investigate 3 pEYS606 doses levels (lower, intermediate and higher dose) over 3 cohorts. Part 2, the extension phase will confirm to safety of the maximum tolerated dose from Part 1 and allow a preliminary assessment of efficacy.

Clinical Study Identifier: NCT03308045

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.